VANCOUVER, British Columbia, October 16, 2025--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company ...
Clinical Trials of ADCs for the Treatment of B-cell Malignancies Five ADCs targeting the B-lineage antigens CD22, CD19 and CD70 are currently in clinical trials for B-cell malignancies: inotuzumab ...
Researchers have found that restoration of B cell function in BCR signaling deficiencies involves the interaction of CD22, normally an inhibitory factor, with binding partners on the same cell, which ...
Aberrant splicing of messenger RNAs encoding surface antigen CD22 leads to downregulation of this protein in pediatric B-lymphoblastic leukemia (B-ALL), rendering malignant cells resistant to the ...
PLEASANTON, Calif. & NANJING, China--(BUSINESS WIRE)--IASO Biotherapeutics, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and ...
Microglia tend to get off-kilter in Alzheimer’s and other neurodegenerative diseases. Now, researchers in Tony Wyss-Coray’s lab at Stanford University believe they have discovered a means of restoring ...
PLEASANTON, Calif. & NANJING, China--(BUSINESS WIRE)--First sentence of release should read: "...has been accepted by the China National Medical Products Administration (NMPA)..." (instead of "...has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results